Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5320MR)

This product GTTS-WQ5320MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5320MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10574MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ14596MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ5793MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ715MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ5427MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ5960MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ4772MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ12628MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW